Navigation Links
MAP Pharmaceuticals Announces Presentations at the American Thoracic Society International Conference
Date:5/14/2009

MOUNTAIN VIEW, Calif., May 14 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it will present three posters on its Unit Dose Budesonide (UDB) pediatric asthma therapy clinical program and one poster on its MAP0005 formoterol-budesonide combination asthma therapy program at ATS 2009, the International Conference of the American Thoracic Society, in San Diego on May 18, 2009.

The four posters can be viewed on Monday, May 18 between 8:15 a.m. and 4:00 p.m. Pacific Time. The presentations are titled:

  • "Unit Dose Budesonide (UDB): A New Submicron Dispersion of Nebulizable Budesonide Studied in 360 Children 12 Months to 8 Years Old with Mild to Moderate Persistent Asthma--The CASTLE I Study"
  • "A Novel Budesonide Formulation for Nebulization Significantly Improves the Amount of Drug Emitted over One Minute in a Simulated Pediatric Tidal Breathing Model"
  • "A Novel Aqueous Dispersion of Budesonide Significantly Improves the Aerodynamic Particle Sizing Distribution of Budesonide from Various Jet Nebulizers Compared to a Marketed Budesonide Suspension"
  • "Comparative Pharmacodynamics and Pharmacokinetics of MAP0005 (Formoterol-Budesonide Combination Particles Delivered via the Tempo(R) Inhaler) in Mild to Moderate Asthmatics"

Copies of the posters will be available under the Publications tab of the MAP Pharmaceuticals website on Monday, May 18.

About MAP Pharmaceuticals

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for children and adults suffering from chronic conditions that are not adequately treated by currently available medicines. The company has two product candidates in Phase 3 clinical development. Unit Dose Budesonide is being developed in collaboration with AstraZeneca for the potential treatment of asthma in children, and MAP0004 is being developed for the potential treatment of migraine. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk, by capitalizing on their known safety, efficacy and commercialization history.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

    Contact:
    MAP Pharmaceuticals, Inc.
    Lisa Borland
    Media Contact
    650-386-3122
    lborland@mappharma.com


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage
2. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
3. Transcept Pharmaceuticals Reports First Quarter 2009 Financial Results
4. MAP Pharmaceuticals to Present at the Deutsche Bank Securities 34th Annual Health Care Conference
5. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for its Third Quarter of FY 2009
6. Celator(R) Pharmaceuticals to Present at 2009 BIO International Convention
7. Arena Pharmaceuticals to Present at the 34th Annual Deutsche Bank Health Care Conference
8. Onyx Pharmaceuticals to Present at the Deutsche Bank 34th Annual Health Care Conference
9. Jiangbo Pharmaceuticals, Inc. to Present at CCG IRs China Rising Conference in New York
10. Vion Pharmaceuticals Reports 2009 First Quarter Results
11. Jiangbo Pharmaceuticals Announces New Ticker (JGBO) and CUSIP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... ... the expansion of its Medication Counseling Centers to address market needs. To support ... MCC staff by more than 60 percent over the past 6 months. The ...
(Date:1/24/2017)... ... January 24, 2017 , ... In comments ... Research Institute (PCORI) for developing a data access and sharing policy. The nation’s ... data sharing plan as part of award applications, and earmarking specified amounts of ...
(Date:1/24/2017)... ... January 24, 2017 , ... The ... the Annual Enrollment Period (AEP) and the Open Enrollment Period (OEP). 2016 was ... coverage. Mainly, people are witnessing higher deductibles, rising premiums, and few choices with ...
(Date:1/24/2017)... ... January 24, 2017 , ... PeroxyChem Food and Beverage Safety ... (PACE), at the International Production and Processing Expo (IPPE) in Atlanta, Georgia from ... technology that is used in poultry processing facilities to provide constant, real-time data ...
(Date:1/24/2017)... ... January 24, 2017 , ... Manzo Pharmaceuticals, LLC., announced that ... Trademark by the United States Patent and Trademark Office. The purpose of ... consumers into thinking that other products are similar to the patented Lacto-Freedom Probiotic. ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... Research and Markets has announced the addition ... - Forecast to 2025" report to their offering. ... Global Optogenetics Market is ... next decade to reach approximately $76.24 million by 2025. ... growing count of labs using optogentic techniques for neurosciences, quick growth ...
(Date:1/24/2017)... -- For today, Stock-Callers.com scans the following Biotechnology ... Biopharmaceuticals Inc. (NASDAQ: ALDR ), BioDelivery Sciences International ... EGLT ). These equities are part of the ... rd , 2017, with the NYSE Health Care Index dropping ... S&P 500 also were down 0.3% as a group. These ...
(Date:1/24/2017)... INTRODUCTION Injectable drug delivery systems have ... vials to prefilled syringes, auto-injectors, pen injectors and ... preferred devices for parenteral administration of drugs. Specifically, ... strongly over the past several years. A growing ... format for delivering drugs. The popularity of prefilled ...
Breaking Medicine Technology: